ArticleJournal of ginseng research2026
Ginsenoside Rg5 alleviates allergic rhinitis in rats by modulating nasal microbiota by inhibiting JAK2/STAT3/BCL-2 and MAPK signaling.
Article in Journal of ginseng research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Allergic rhinitis (AR) is a non infectious chronic inflammatory disease of nasal mucosa mediated by IgE and driven by type 2 immune response. Ginsenoside Rg5 (Rg5) is a bioactive compound derived from ginseng, but its effect on AR is unknown. Objective: This study investigated the therapeutic potential of Rg5 in toluene diisocyanate (TDI)-induced AR and explored its potential mechanism involving JAK2/SATAT3/BCL-2 and MAPK signaling pathways as well as nasal microbiota regulation. Methods: AR model was established by TDI sensitization and different doses of Rg5 were administered to assess symptom scores, IgE, His and cytokine levels. Nasal mucosal tissues and lung tissues were analyzed histopathologically for key proteins in the JAK2/STAT3/BCL-2 and MAPK pathways in the nasal mucosa. Nasal microbiota composition was assessed using 16S rRNA sequencing and signaling pathway correlation analysis was performed. Results: Rg5 significantly reduces IgE, His, and pro-inflammatory factors, increases anti-inflammatory factors, mitigates damage to the nasal mucosa and lung tissues, thereby alleviates nasal symptoms. It suppresses the activation of JAK2/STAT3 and MAPK pathways and upregulates BCL-2 expression. It also increases the abundance of Conclusion: Ginsenoside Rg5 acts synergistically through the JAK2/STAT3/BCL-2 and MAPK signaling pathways while restoring nasal microbiota homeostasis and attenuating TDI-induced AR symptoms, highlighting its potential as a novel therapeutic agent for AR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.